Provided by Tiger Fintech (Singapore) Pte. Ltd.

LUYE PHARMA

2.410
+0.0903.88%
Volume:24.41M
Turnover:57.96M
Market Cap:9.07B
PE:15.73
High:2.410
Open:2.330
Low:2.330
Close:2.320
Loading ...

Investors Appear Satisfied With Luye Pharma Group Ltd.'s (HKG:2186) Prospects

Simply Wall St.
·
11 Feb

Luye Pharma Group Enrolls First Patient in Phase II Trial for New Huntington's Disease Drug

MT Newswires Live
·
16 Jan

Luye Pharma Gets US FDA Approval for Clinical Trials for Schizophrenia Drug

MT Newswires Live
·
15 Jan

BRIEF-Luye Pharma Says Approval Obtained For Group's New Drug Ly03020 For Clinical Trials In U.S.

Reuters
·
14 Jan

Luye Pharma - Approval Obtained for Group's New Drug Ly03020 for Clinical Trials in U.S.

THOMSON REUTERS
·
14 Jan

Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Simply Wall St.
·
22 Dec 2024

BRIEF-Luye Pharma Says Executive Chairman Bought Shares Of Co

Reuters
·
18 Dec 2024

Luye Pharma - Executive Chairman Bought 2.0 Mln Ordinary Shares of Co at Average Price of HK$2.2299 per Share on Market

THOMSON REUTERS
·
18 Dec 2024

Zhongtai International Starts Luye Pharma Group at Buy with HK$2.90 Price Target

MT Newswires Live
·
18 Dec 2024

Luye Pharma Group Issues $50 Million Convertible Bonds

MT Newswires
·
16 Dec 2024

Luye Pharma Files for Singapore Listing of $50 Million of Bonds Due in 2025

MT Newswires
·
13 Dec 2024

Luye Pharma Gets Marketing Go-Ahead for Lung Cancer Drug from Chinese Regulator

MT Newswires Live
·
03 Dec 2024

Luye Pharma - Approval of Zepzelca (Lurbinectedin for Injection) for Marketing in Mainland China by Nmpa

THOMSON REUTERS
·
03 Dec 2024

Three Luye Pharma Products Included in National Reimbursement Drug List

MT Newswires Live
·
28 Nov 2024

Luye Pharma's Anti-Depression Drug Gets IND Approval in China

MT Newswires Live
·
11 Nov 2024

Luye Pharma - Approval Obtained for Class 1 Innovative Antidepressant Ly03021 for Clinical Trials in China

THOMSON REUTERS
·
11 Nov 2024